Effects of post‐hepatic portoenterostomy adjuvant therapy on liver transplantation in children with biliary atresia: A systematic review
Authors:
- Bianca Ferraz de Almeida SilvaBSBianca Ferraz de Almeida Silva
- Alice Palmeira Nascimento CerqueiraACAlice Palmeira Nascimento Cerqueira
- Breno Oliveira MarquesBMBreno Oliveira Marques
- Gabriela Garcia de Carvalho LagunaGLGabriela Garcia de Carvalho Laguna
- Gabrielle dos Santos AguiarGAGabrielle dos Santos Aguiar
- Luana Leal GonzagaLGLuana Leal Gonzaga
- Raquel Teles de LacerdaRLRaquel Teles de Lacerda
- Natalia Oliveira e SilvaNSNatalia Oliveira e Silva
Open Access
- 13 July 2026
- journal article
- review article
- Published by Wiley in JPGN Reports
- Vol. 7 (4) , 572-581
Abstract
Objectives: Biliary atresia (BA) is a cholangiopathy characterized by obstruction of the intrahepatic and extrahepatic bile ducts. Hepatic portoenterostomy (HPE) is the primary palliative treatment and there is still an urgent need to improve post‐HPE management. This study aims to identify post‐HPE adjuvant therapies associated with reducing or delaying the need for liver transplantation in children with BA. Methods: This systematic review was registered on the PROSPERO platform (ID: CRD42024553671). Studies were extracted from the following databases: PubMed, Web of Science, Lilacs, and Scielo. Original articles published between 2003 and 2025 in English, Portuguese, and Spanish were included, while studies involving adults, animals, or unrelated topics were excluded. Results: A total of 870 studies were identified, and after applying eligibility criteria, 16 articles were selected. The studies indicated that corticosteroids alone as adjuvant therapy were not associated with improved native liver survival. However, observational studies indicated that corticosteroid therapy combined with antibiotics, anticholestatics, and immunoglobulin may be associated with improvements in jaundice, although only two studies reported increased liver survival. Rectal budesonide demonstrated promising short and long‐term results in children with nonsyndromic BA. Conclusions: The use of adjuvant therapy after HPE was associated with improvements in jaundice and cholangitis and, in some studies, with increased liver survival. However, the findings are conflicting and heterogeneous. Further research is needed, with standardized therapeutic approaches to enable more comprehensive analyses.Keywords
This publication has 42 references indexed in Scilit:
- Rectal budesonide: A potential game changer after Kasai hepatoportoenterostomyJournal of Pediatric Gastroenterology and Nutrition, 2025
- Prednisolone administration monitored by postoperative stool color achieves high jaundice clearance after laparoscopic portoenterostomy for biliary atresiaPediatric Surgery International, 2023
- Laparoscopic versus open Kasai procedure for biliary atresia: long-term results of a randomized clinical trialPediatric Surgery International, 2023
- Biliary Atresia: Clinical and Research Challenges for the Twenty‐First CenturyHepatology, 2018
- Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patientsPediatric Surgery International, 2018
- Use of Corticosteroids After Hepatoportoenterostomy for Bile Drainage in Infants With Biliary AtresiaJAMA, 2014
- Evaluating patients’ outcome post-Kasai operation: a 19-year experience with modification of the hepatic portoenterostomy and applying a novel steroid therapy regimenPediatric Surgery International, 2010
- Universal screening for biliary atresia using an infant stool color card in Taiwan†Hepatology, 2007
- Randomized, double-blind, placebo-controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresiaHepatology, 2007
- Serial circulating markers of inflammation in biliary atresia—Evolution of the post-operative inflammatory processHepatology, 2007